LSE:WISE 22 November 2025

April 1, 2026, 1:59 PM EDT. Revolution Medicines (RVMD) gained 4.9% recently, continuing a 90-day 22.1% rally and a 1-year shareholder return near 190%. The stock price stands close to $97.25, above a bearish fair value estimate of $92.22 but far below a bullish discounted cash flow (DCF) valuation of $523.04. Analysts projecting fair value at $92.22 highlight risks tied to its zero current revenue and heavy planned 2026 spending of $1.6-1.7 billion. The debate centers on whether the market price already reflects anticipated growth from late-stage RAS(ON) drug trials targeting large tumors. Investors face a contrast between cautious price targets and models suggesting significant upside if development milestones translate to stronger earnings.